A Phase 3 interventional study of eltrombopag olamine (SB-497115-GR) in Purpura, Thrombocytopaenic, Idiopathic, sponsored by Novartis Pharmaceuticals. Completed at 110 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 2nd largest by enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 2nd registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Renata PLC · Sites in Bangladesh
Ages 18–70
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis: 4 open now, 7 under way, 2 of them phase 3. Of 7 finished, 6 (86%) have results posted.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one has the largest enrollment of the 12 interventional ones that give a count, is the only one that started in 2006, is one of 4 in phase 3, and was the 1st registered.
Novartis’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2006.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 17 in Purpura, Thrombocytopenic, Idiopathic:
This tab as a report to print or save as PDF → With an account.
An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/μL will be investigated.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
This study's enrollment of 302 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Browse Purpura, Thrombocytopenic, Idiopathic studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Other Eligibility Criteria Considerations:
To assess any potential impact on subject eligibility with regard to safety, the investigator must refer to the following document(s) for detailed information regarding warnings, precautions, , adverse events, and other significant data pertaining to the investigational product(s) being used in this study: CIB, SPM.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label eltrombopag
Drug: eltrombopag olamine (SB-497115-GR)
Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.
Overall Summary of On-Therapy Adverse Events (Safety Population)
All safety evaluation findings considered to be adverse events are reported in the Adverse Event section.
Time frame: Start date was the first dose of investigational product and up to the day after the last dose . Post-therapy: start date was more than 1 day after the last dose and up to 30 days after last dose of investigational product up to week 364
Subjects Achieving Maximum Platelet Counts Greater Than or Equal to 30 Gi/L or 50 Gi/L in the Absence of Rescue Medication
Subjects who achieved maximum platelet count at least once during treatment. All platelet counts after an on-study splenectomy are not classed as responses. Platelet counts within 7 days after a platelet transfusion are not classed as responses. Platelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.
Time frame: Baseline up to 2 years
Summary of Subjects Achieving Platelet Count Levels by Week, in the Absence of Rescue Medication
If a subject has more than 1 platelet count result within a week, the lowest value observed is used to determine response. All platelet counts after an on-study splenectomy are not classed as responses. Platelet counts within 7 days after a platelet transfusion are not classed as responses. Platelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.
Time frame: Baseline up to Year 7/Week 364
Number of Subjects Who Responded to Eltrombopag in a Previous Study and Who Respond to Retreatment With a Rise in Platelet Count to Either ≥ 50,000/µL or ≥30,000/µL
Responder in TRA100773: Platelet count 50 Gi/L and 2 x baseline (BL) at last on-treatment assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL), 50 Gi/L, and 30 Gi/L at any time. Responder in RAISE: Platelet count 50GI/L and 2 x baseline at Week 6 assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline, 50 Gi/L, and 30 Gi/L at any time. Responder in REPEAT: Platelet count 50 GI/L and 2 x baseline (BL) at Week 6 assessment in Cycle 1. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL) 50 Gi/L, and 30 Gi/L at any time.
Time frame: Baseline up to 2 years
Number of Participants With Reduction and/or Sparing of Concomitant ITP Therapies, While Maintaining a Platelet Count ≥ 50,000/mL.
Sustain reduct: Sustained reduction 1 Denominator is number of subjects taking an ITP medication at baseline. 2 Denominator is number of subjects with a sustained reduction. Note: Sustained reduction defined as reduction from baseline in dose and/or frequency which is maintained for at least 4 weeks. Excludes sustained reductions started more than 1 day after last dose.
Time frame: Baseline up to 2 years
Number of Subjects Who Required Rescue Therapy During Treatment With Eltrombopag.
Rescue treatment is defined as a composite of: new ITP medication, increased dose of a concomitant ITP medication, platelet transfusion, and splenectomy. Subjects may have received more than 1 type of rescue therapy
Time frame: Baseline up to 2 years
Maximum ITP Bleeding Score at Any Time During the Study During All Stages.
The ITP bleeding score is a tool which has been designed specifically to assess the bruising and bleeding in patients with ITP across body sites, ranging from mild to severe. The WHO Grades were dichotomized into the following categories: - Grade 0, No bleeding -Grade 1 to 4, Any bleeding -Grade 0 to 1: No clinically significant bleeding -Grade 2 to 4 Clinically significant bleeding
Time frame: Baseline up to 2 years
Best Post-Baseline Change in SF-36v2 Questionnaire Score From Any Time Point Compared With Baseline
The SF-36v2 assessment tool was used to obtain information about subjects' general health status and health-related quality of life. Until a formal assessment of minimal clinically important differences (MCID) is performed, changes from baseline of more than 0.5 standard deviations are suggested as clinically meaningful. Scores were transformed to a 0-100 point scale, with higher scores representing more positive answers. Scores were normalized to have a mean of 50 and SD of 10 to allow for comparison with outcomes from other chronic diseases. Recall period is the past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group
Time frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years
Best Post-Baseline Change in the Short Form of the Motivation and Energy Scale (MEI-SF) From Any Time Point Compared With Baseline
The MEI-SF (18 questions) was used to measure the reductions in mental energy, physical energy, and social motivation, either as symptoms of chronic ITP or as a side effect of pharmacotherapy. Minimal clinically important differences are estimated as 0.5 standard deviations or 7.5 points. All items use either a 7-level (0 to 6) or 5-level (0 to 4) response scale; items with a 5-level response scale were rescaled to 7-levels, and items were reverse-scored as necessary such that higher scores represent higher HRQoL Total score ranges from 0 to 108 points. Recall period is past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group
Time frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years
Best Post-Baseline Change in the FACIT-Fatigue 13 Item Subscale Score From Any Time Point Compared to Baseline
The FACIT-Fatigue consists of 13 questions in which patients rate the frequency (0-4) of symptoms of fatigue, in terms of tiredness, weakness, and fatigue Items were reverse-scored as necessary such that higher scores represent higher HRQoL Total score ranges from 0 to 52.Using anchor-based estimates, the minimally important difference in this subscale is 3.0 points. Recall period is past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group
Time frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years
Best Post-Baseline Change in the FACT-TH6 at Any Time Point Compared to Baseline
The FACT-TH6 consists of 6 questions in which patients rate (0-4) their general degree of worry related to bleeding and bruising, and resulting activity impairment and frustration. Although the six items do not constitute a formal domain or subscale of the FACT-Th assessment tool, these items had been identified by focus groups of patients with chronic ITP as important indicators of their HRQoL. Items were reverse-scored as necessary such that higher scores represent higher HRQoL. Total scores ranged from 0 to 24. Recall period is not specified. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group
Time frame: Baseline, beginning of each stage, change in therapy and minimum frequency of every 3 months during stages, prior to early discontinuation, up to 2 years
Subjects were previously enrolled in a study of eltrombopag: TRA100773A, TRA100773B, TRA102537/RAISE, or TRA108057/REPEAT. Eligibility of consenting subjects was assessed during the screening period of up to 28 days prior to Day 1 of treatment.
| Milestone | Eltrombopag |
|---|---|
| Started | 302 |
| Subjects from tra100773a | 51 |
| Subjects from tra100773b | 61 |
| Subjects from tra102537 raise | 146 |
| Subjects from tra108057 repeat | 43 |
| Unknown - not from previous trial | 1 |
| Completed | 135 |
| Not completed | 167 |
| Withdrew: Adverse event | 42 |
| Withdrew: Withdrawal by subject | 39 |
| Withdrew: Various -follow up w clinical team | 39 |
| Withdrew: Lack of efficacy | 32 |
| Withdrew: Non-compliance | 8 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Protocol violation | 3 |
All safety evaluation findings considered to be adverse events are reported in the Adverse Event section.
| Participants | Eltrombopag |
|---|---|
| Any adverse event | 277 |
| Any serious adverse event | 96 |
| Adverse events related to study medication | 133 |
| Adverse events leading to withdrawal | 41 |
| Serious adverse events leading withdrawal | 28 |
Subjects who achieved maximum platelet count at least once during treatment. All platelet counts after an on-study splenectomy are not classed as responses. Platelet counts within 7 days after a platelet transfusion are not classed as responses. Platelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.
| Participants | Eltrombopag |
|---|---|
| Baseline Platelet counts >= 30 Gi/L, | 91 |
| Baseline Platelet counts >= 50 Gi/L, | 42 |
| Maximum Platelet Count >= 30 Gi/L | 276 |
| Maximum Platelet Count >= 50 Gi/L | 259 |
If a subject has more than 1 platelet count result within a week, the lowest value observed is used to determine response. All platelet counts after an on-study splenectomy are not classed as responses. Platelet counts within 7 days after a platelet transfusion are not classed as responses. Platelet counts while taking an increased ITP medication or within 6 weeks after the end of an increased ITP medication are not classed as responses.
| Participants | Eltrombopag |
|---|---|
| Baseline Platelet counts >= 30 Gi/L, n=302 | 91 |
| Baseline Platelet counts >= 50 Gi/L, n=302 | 42 |
| Week 1 Platelet Count >= 30 Gi/L n=293 | 172 |
| Week 1 Platelet Count >= 50 Gi/L n=293 | 127 |
| Week 2 Platelet Count >= 30 Gi/L n=288 | 199 |
| Week 2 Platelet Count >= 50 Gi/L n=288 | 165 |
| Week 3 Platelet Count >= 30 Gi/L n=275 | 192 |
| Week 3 Platelet Count >= 50 Gi/L n=275 | 159 |
| Week 4 Platelet Count >= 30 Gi/L n=275 | 192 |
| Week 4 Platelet Count >= 50 Gi/L n=275 | 149 |
| Week 5 Platelet Count >= 30 Gi/L n=274 | 197 |
| Week 5 Platelet Count >= 50 Gi/L n=274 | 159 |
| Week 6 Platelet Count >= 30 Gi/L n=276 | 203 |
| Week 6 Platelet Count >= 50 Gi/L n=276 | 169 |
| Week 12 Platelet Count >= 30 Gi/L n=197 | 147 |
| Week 12 Platelet Count >= 50 Gi/L n=197 | 120 |
| Month 6/Week 26 Platelet Count >= 30 Gi/L n=130 | 93 |
| Month 6/Week 26 Platelet Count >= 50 Gi/L n=130 | 82 |
| Year 1/Week 52 Platelet Count >= 30 Gi/L n=83 | 62 |
| Year 1/Week 52 Platelet Count >= 50 Gi/L n=83 | 50 |
| Year 1.5/Week 78 Platelet Count >= 30 Gi/L n=63 | 47 |
| Year 1.5/Week78 Platelet Count >= 50 Gi/L n=63 | 41 |
| Year 2/Week 104 Platelet Count >= 30 Gi/L n=59 | 46 |
| Year 2/Week 104 Platelet Count >= 50 Gi/L n=59 | 42 |
| Year 2.5/Week 130 Platelet Count >= 30 Gi/L n=42 | 32 |
| Year 2.5/Week 130 Platelet Count >= 50 Gi/L n=42 | 28 |
| Year 3/Week 156 Platelet Count >= 30 Gi/L n=27 | 22 |
| Year 3/Week 156 Platelet Count >= 50 Gi/L n=27 | 19 |
| Year 3.5/Week 182 Platelet Count >= 30 Gi/L n=23 | 19 |
| Year 3.5/Week 182 Platelet Count >= 50 Gi/L n=23 | 17 |
| Year 4/Week 208 Platelet Count >= 30 Gi/L n=17 | 12 |
| Year 4/Week 208 Platelet Count >= 50 Gi/L n=17 | 11 |
| Year 4.5/Week 234 Platelet Count >= 30 Gi/L n=15 | 13 |
| Year 4.5/Week 234 Platelet Count >= 50 Gi/L n=15 | 12 |
| Year 5/Week 260 Platelet Count >= 30 Gi/L n=9 | 6 |
| Year 5/Week 260 Platelet Count >= 50 Gi/L n=9 | 6 |
| Year 5.5/Week 286 Platelet Count >= 30 Gi/L n=9 | 7 |
| Year 5.5/Week 286 Platelet Count >= 50 Gi/L n=9 | 7 |
| Year 6/Week 312 Platelet Count >= 30 Gi/L n=9 | 7 |
| Year 6/Week 312 Platelet Count >= 50 Gi/L n=9 | 7 |
| Year 6.5/Week 338 Platelet Count >= 30 Gi/L n=5 | 3 |
| Year 6.5/Week 338 Platelet Count >= 50 Gi/L n=5 | 3 |
| Year 7/Week 364 Platelet Count >= 30 Gi/L n=3 | 3 |
| Year 7/Week 364 Platelet Count >= 50 Gi/L n=3 | 3 |
Responder in TRA100773: Platelet count 50 Gi/L and 2 x baseline (BL) at last on-treatment assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL), 50 Gi/L, and 30 Gi/L at any time. Responder in RAISE: Platelet count 50GI/L and 2 x baseline at Week 6 assessment. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline, 50 Gi/L, and 30 Gi/L at any time. Responder in REPEAT: Platelet count 50 GI/L and 2 x baseline (BL) at Week 6 assessment in Cycle 1. Responders in EXTEND: Platelet count 50 Gi/L and 2 x baseline (BL) 50 Gi/L, and 30 Gi/L at any time.
| Participants | Eltrombopag |
|---|---|
| TRA100773 Responders >= 50 Gi/L in EXTEND, n=51 | 49 |
| TRA100773 >=50 Gi/L and 2 x BL in EXTEND, n=51 | 47 |
| TRA100773 Responders >= 30 Gi/L in EXTEND, n=51 | 49 |
| RAISE Responders >= 50 Gi/L in EXTEND, n=59 | 54 |
| RAISE >= 50 Gi/L and 2 x BL in EXTEND, n=59 | 53 |
| RAISE Responders >= 30 Gi/L in EXTEND, n=51 | 55 |
| REPEAT Responders >= 50 Gi/L in EXTEND, n=36 | 33 |
| REPEAT>= 50 Gi/L and 2 x BL in EXTEND, n=36 | 33 |
| REPEAT Responders >= 30 Gi/L in EXTEND, n=36 | 35 |
Sustain reduct: Sustained reduction 1 Denominator is number of subjects taking an ITP medication at baseline. 2 Denominator is number of subjects with a sustained reduction. Note: Sustained reduction defined as reduction from baseline in dose and/or frequency which is maintained for at least 4 weeks. Excludes sustained reductions started more than 1 day after last dose.
| Participants | Eltrombopag |
|---|---|
| ITP medication at baseline | 101 |
| Sustain reduct or stop at least 1 med [1] n=101 | 71 |
| Permanently stopping at least 1 ITP med [1] n=101 | 53 |
| Sustained reduction[1] n=101 | 70 |
| Maximum sustained reduction ≥ 24 weeks[2] n=70 | 66 |
Rescue treatment is defined as a composite of: new ITP medication, increased dose of a concomitant ITP medication, platelet transfusion, and splenectomy. Subjects may have received more than 1 type of rescue therapy
| Participants | Eltrombopag |
|---|---|
| New ITP medication, n=103 | 82 |
| Increase in dose of ITP med from baseline, n=103 | 27 |
| Platelet transfusion, n=103 | 21 |
| Splenectomy, n=103 | 3 |
The ITP bleeding score is a tool which has been designed specifically to assess the bruising and bleeding in patients with ITP across body sites, ranging from mild to severe. The WHO Grades were dichotomized into the following categories: - Grade 0, No bleeding -Grade 1 to 4, Any bleeding -Grade 0 to 1: No clinically significant bleeding -Grade 2 to 4 Clinically significant bleeding
| Participants | Eltrombopag |
|---|---|
| Epistaxis n=300 Grade 0 | 204 |
| Epistaxis n=300 Grade 1 | 65 |
| Epistaxis n=300 Grade 2 | 31 |
| Gastrointestinal n=300 Grade 0 | 264 |
| Gastrointestinal n=300 Grade 1 | 26 |
| Gastrointestinal n=300 Grade 2 | 10 |
| Genitourinary n=300 Grade 0 | 262 |
| Genitourinary n=300 Grade 1 | 29 |
| Genitourinary n=300 Grade 2 | 9 |
| Gynecologic n=108 Grade 0 | 68 |
| Gynecologic n=108 Grade 1 | 15 |
| Gynecologic n=108 Grade 2 | 25 |
| Intracerebral hemorrhage n=300 Grade 0 | 297 |
| Intracerebral hemorrhage n=300 Grade 1 | 3 |
| Intracerebral hemorrhage n=300 Grade 2 | 0 |
| Ocular n=300 Grade 0 | 258 |
| Ocular n=300 Grade 1 | 37 |
| Ocular n=300 Grade 2 | 5 |
| Oral n=300 Grade 0 | 191 |
| Oral n=300 Grade 1 | 81 |
| Oral n=300 Grade 2 | 28 |
| Pulmonary n=300 Grade 0 | 287 |
| Pulmonary n=300 Grade 1 | 13 |
| Pulmonary n=300 Grade 2 | 0 |
| Skin, ecchymosis n=300 Grade 0 | 74 |
| Skin, ecchymosis n=300 Grade 1 | 159 |
| Skin, ecchymosis n=300 Grade 2 | 67 |
| Skin, petechiae n=300 Grade 0 | 142 |
| Skin, petechiae n=300 Grade 1 | 126 |
| Skin, petechiae n=300 Grade 2 | 32 |
The SF-36v2 assessment tool was used to obtain information about subjects' general health status and health-related quality of life. Until a formal assessment of minimal clinically important differences (MCID) is performed, changes from baseline of more than 0.5 standard deviations are suggested as clinically meaningful. Scores were transformed to a 0-100 point scale, with higher scores representing more positive answers. Scores were normalized to have a mean of 50 and SD of 10 to allow for comparison with outcomes from other chronic diseases. Recall period is the past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group
| Points on a scale | Eltrombopag |
|---|---|
| SF-36v2 Physical function (n=273 | 12.0 (9.6 to 14.5) |
| SF-36v2 Physical role (n=273) | 14.2 (11.5 to 16.9) |
| SF-36v2 Bodily pain (n=273) | 14.5 (11.6 to 17.4) |
| SF-36v2 General health (n=273) | 11.1 (9.0 to 13.1) |
| SF-36v2 Vitality (n=290) | 13.9 (11.6 to 16.3) |
| SF-36v2 Social function (n=290) | 12.6 (10.2 to 15.1) |
| SF-36v2 Emotional role (n=290) | 11.4 (8.7 to 14.0) |
| SF-36v2 Mental health (n=290) | 11.3 (9.4 to 13.3) |
| SF-36v2 Physical component summary (n=273) | 5.3 (4.5 to 6.2) |
| SF-36v2 Mental component summary (n=290) | 5.8 (4.6 to 6.9) |
The MEI-SF (18 questions) was used to measure the reductions in mental energy, physical energy, and social motivation, either as symptoms of chronic ITP or as a side effect of pharmacotherapy. Minimal clinically important differences are estimated as 0.5 standard deviations or 7.5 points. All items use either a 7-level (0 to 6) or 5-level (0 to 4) response scale; items with a 5-level response scale were rescaled to 7-levels, and items were reverse-scored as necessary such that higher scores represent higher HRQoL Total score ranges from 0 to 108 points. Recall period is past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group
| Points on a scale | Eltrombopag |
|---|---|
| Best Post-Baseline Change in the Short Form of the Motivation and Energy Scale (MEI-SF) From Any Time Point Compared With Baseline | 11.3 (9.1 to 13.5) |
The FACIT-Fatigue consists of 13 questions in which patients rate the frequency (0-4) of symptoms of fatigue, in terms of tiredness, weakness, and fatigue Items were reverse-scored as necessary such that higher scores represent higher HRQoL Total score ranges from 0 to 52.Using anchor-based estimates, the minimally important difference in this subscale is 3.0 points. Recall period is past week prior to administration. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group
| Points on a scale | Eltrombopag |
|---|---|
| Best Post-Baseline Change in the FACIT-Fatigue 13 Item Subscale Score From Any Time Point Compared to Baseline | 6.9 (5.7 to 8.1) |
The FACT-TH6 consists of 6 questions in which patients rate (0-4) their general degree of worry related to bleeding and bruising, and resulting activity impairment and frustration. Although the six items do not constitute a formal domain or subscale of the FACT-Th assessment tool, these items had been identified by focus groups of patients with chronic ITP as important indicators of their HRQoL. Items were reverse-scored as necessary such that higher scores represent higher HRQoL. Total scores ranged from 0 to 24. Recall period is not specified. The change in scores was measured at the transitioning period and immediately prior to withdrawal/completion over 2 years, and the mean of these measurements was recorded to calculate the change from baseline and the best post baseline change score was reported for the entire group
| Points on a scale | Eltrombopag |
|---|---|
| Best Post-Baseline Change in the FACT-TH6 at Any Time Point Compared to Baseline | 4.0 (3.4 to 4.6) |
Collected over Treatment + 1 Day: start date was between the first dose of investigational product and up to the day after the last dose . Post-therapy: start date was more than 1 day after the last dose and up to 30 days after last dose of investigational product. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag, Treatment + 1 Day | — | 96/302 (31.8%) | 253/302 (83.8%) |
| Eltrombopag, >1 to 30 Days Post-Therapy | — | 10/302 (3.3%) | 28/302 (9.3%) |
| Event | Eltrombopag, Treatment + 1 Day | Eltrombopag, >1 to 30 Days Post-Therapy |
|---|---|---|
| CataractEye disorders | 16/302 | 0/302 |
| PneumoniaInfections and infestations | 8/302 | 1/302 |
| AnaemiaBlood and lymphatic system disorders | 5/302 | 1/302 |
| Alanine aminotransferase increasedInvestigations | 5/302 | 0/302 |
| Aspartate aminotransferase increasedInvestigations | 4/302 | 0/302 |
| Blood bilirubin increasedInvestigations | 4/302 | 0/302 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 4/302 | 0/302 |
| Deep vein thrombosisVascular disorders | 4/302 | 0/302 |
| Urinary tract infectionInfections and infestations | 3/302 | 0/302 |
| Platelet count decreasedInvestigations | 3/302 | 0/302 |
| Event | Eltrombopag, Treatment + 1 Day | Eltrombopag, >1 to 30 Days Post-Therapy |
|---|---|---|
| HeadacheNervous system disorders | 86/302 | 3/302 |
| NasopharyngitisInfections and infestations | 74/302 | 2/302 |
| Upper respiratory tract infectionInfections and infestations | 69/302 | 5/302 |
| FatigueGeneral disorders | 50/302 | 4/302 |
| DiarrhoeaGastrointestinal disorders | 46/302 | 3/302 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 45/302 | 0/302 |
| Back painMusculoskeletal and connective tissue disorders | 39/302 | 0/302 |
| NauseaGastrointestinal disorders | 34/302 | 1/302 |
| Urinary tract infectionInfections and infestations | 32/302 | 2/302 |
| CoughRespiratory, thoracic and mediastinal disorders | 32/302 | 0/302 |
| Age, Continuous(Years) | Eltrombopag |
|---|---|
| Mean | 48.9 ± 15.61 |
| Sex: Female, Male(Participants) | Eltrombopag |
|---|---|
| Female | 201 |
| Male | 101 |
| Concomitant ITP Medication at Baseline(Participant) | Eltrombopag |
|---|---|
| Yes | 101 |
| No | 201 |
| Splenectomy Status at Baseline(Participants) | Eltrombopag |
|---|---|
| Yes | 115 |
| No | 187 |
| Baseline Platelet Count(Participants) | Eltrombopag |
|---|---|
| <30 Gi/L | 211 |
| 30 - 50 Gi/L | 52 |
| > 50 Gi/L | 39 |
Showing the first 100 of 110 sites across 31 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2006, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →